Saxenda Guide
Saxenda is liraglutide 3.0 mg under its brand name, and it was the first of the GLP-1 receptor agonists to earn an FDA chronic weight management approval in adults (December 23, 2014) and later for adolescents aged 12 and older (December 4, 2020). It is a once-daily subcutaneous injection delivered through a single-patient-use pre-filled pen and is manufactured by Novo Nordisk. The once-weekly drugs that followed it, Wegovy (semaglutide 2.4 mg) in 2021 and Zepbound (tirzepatide) in 2023, have since overtaken it on weight loss. In the head-to-head STEP-8 trial, semaglutide 2.4 mg produced 15.8% mean weight loss versus 6.4% with liraglutide 3.0 mg over 68 weeks. It was the first GLP-1 approved for weight management in adolescents (12 and older, December 2020); Wegovy injection followed in December 2022. Novo Nordisk is discontinuing Saxenda: the FDA drug shortage list says it will be available until January 2027.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
At a Glance
| Generic Name | Liraglutide |
| Brand Names | Saxenda |
| FDA Status | FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity (trials enrolled at BMI ≥30, or ≥27 with a comorbidity) (December 23, 2014); pediatric indication for patients aged 12 years and older with body weight greater than 60 kg and obesity added December 4, 2020. Being discontinued by Novo Nordisk: FDA's drug shortage database lists Saxenda as 'Limited Availability' and says 'Product will be available until discontinuation in January 2027' (reason: discontinuation of manufacture, posted August 25, 2026).[1] |
| Approval Date | December 23, 2014[1] |
How does Saxenda work?
Liraglutide is an acylated, 97%-homologous analog of native human GLP-1, modified with a fatty-acid side chain that lets it bind albumin and resist DPP-4 degradation — extending its half-life from minutes to about 13 hours. Activating GLP-1 receptors in hypothalamic appetite centers reduces hunger and increases satiety, while peripheral effects slow gastric emptying and dampen meal-time glucose excursions. Paired with increased physical activity and a diet reduced in calories, the net result is that patients eat less and keep weight off.[2]
Dosing Schedule
Saxenda uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
What side effects does Saxenda cause?
Common (≥5%): nausea, hypoglycemia (in patients with type 2 diabetes), diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, injection-site reactions. About 9.8% of adult trial patients discontinued for adverse reactions, most commonly nausea (2.9%), vomiting (1.7%), and diarrhea (1.4%). Serious (rare): acute pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury from volume depletion, hypoglycemia (especially when combined with insulin or sulfonylureas), increased heart rate, and serious hypersensitivity reactions including anaphylaxis and angioedema. Boxed warning: liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rodents; relevance to humans is unknown. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]
Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].
Clinical Trial Results
The pivotal trial was SCALE Obesity and Prediabetes (N=3,731 adults, none diabetic; Pi-Sunyer et al. NEJM 2015, PMID 26132939). At 56 weeks Saxenda 3.0 mg had produced mean body-weight loss of 8.4 kg against 2.8 kg on placebo, and 63.2% of treated patients were past the 5% bar against 27.1% on placebo. A second trial, SCALE Sleep Apnea (Blackman et al. 2016, PMID 27005405), showed significantly greater reductions in apnea-hypopnea index alongside weight loss in adults with moderate-to-severe OSA. The SCALE Teens trial (Kelly et al. NEJM 2020, PMID 32233338) supported the December 2020 adolescent (ages 12+) indication, showing reductions in BMI standard deviation score versus placebo over 56 weeks.[2]
Where can you get Saxenda?
Sellers in our register that will dispense liraglutide, or a compounded version of it, after an online consultation — shipped to your door.
Editorial score · methodology
How much does Saxenda cost?
1 seller in the register publishes a price; the lowest starts at $716.50 a month, checked November 2026. What each one charges to start, cheapest at the top. Compounded liraglutide from state-licensed 503A pharmacies is legal under federal compounding law when made for an individual patient[3], and the rules loosen further, to include bulk compounding by 503B outsourcing facilities, only while a molecule sits on the FDA Drug Shortage List[4]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[5]. What you actually pay moves with your dose and with whatever promotion happens to be running.
| Provider | Starting Price | Link | |
|---|---|---|---|
| Cost Plus Drugs | brand | $716.50/mo | Visit |
Saxenda Head-to-Head Comparisons
Short verdict pages setting Saxenda against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.
See all drug-vs-drug verdicts.
Pivotal Saxenda Trial Walkthroughs
The trials that produced the Saxenda label, taken endpoint by endpoint, with the figures read off the source.
Saxenda Reference Cards
One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.
Ranked PubMed Studies on Saxenda
The peer-reviewed studies on Saxenda and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.
Related Research on Saxenda
Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.
Frequently Asked Questions
Sources & methodology — as of November 2026
- 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.